In fact, pilot studies performed in patients with chronic kidney disease (19) and patients with autoimmune liver disease (48) indicate that clinically employed doses of EPO reliably increase frequencies of peripheral blood Tregs. This evidence concerns the gene EPO and chronic kidney disease.